Evidence map›Paper›PMID 32667139›Full record

ArticleJournal of cellular and molecular medicine2020

Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.

Johannes de Munter, Diana Babaevskaya, Erik Ch Wolters, Dmitrii Pavlov, Ekaterina Lysikova, Allan V Kalueff, Anna Gorlova, Margarita Oplatchikova, Igor A Pomytkin, Andrey Proshin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Beneficial Effects of Putative Hydrogen Sulfide (HMolecules (Basel, Switzerland) · 2026
    Article
  4. Tail-rattling in rodents: more than a threat display.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Johannes de MunterDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0001-7583-1464
Diana BabaevskayaLaboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.ORCID 0000-0003-1692-0445
Erik Ch WoltersDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0003-4411-6892
Dmitrii PavlovDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0001-9120-7266
Ekaterina LysikovaInstitute of Physiologically Active Compounds, Moscow, Russia.ORCID 0000-0001-6521-3793
Allan V KalueffFaculty of Biology, Ural Federal University, Ekaterinburg, Russia.ORCID 0000-0002-7525-1950
Anna GorlovaDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-9345-7880
Margarita OplatchikovaLaboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.ORCID 0000-0002-7641-2330
Igor A PomytkinDepartment of Advanced Cell Technologies, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.ORCID 0000-0002-8426-3371
Andrey ProshinPK Anokhin Research Institute of Normal Physiology, Moscow, Russia.ORCID 0000-0002-7258-7870
Aleksei UmriukhinLaboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.ORCID 0000-0003-1637-4245
Klaus-Peter LeschDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0001-8348-153X
Tatyana StrekalovaDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0001-9937-5600
Sechenov University · RUMaastricht University · NLInstitute of Normal Physiology named after P.K. Anokhin · RUInstitute of Physiologically Active Compounds · RUUral Federal University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic mutations in FUS, a DNA/RNA-binding protein, are associated with inherited forms of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A novel transgenic FUS[1-359]-tg mouse line recapitulates core hallmarks of human ALS in the spinal cord, including neuroinflammation and neurodegeneration, ensuing muscle atrophy and paralysis, as well as brain pathomorphological signs of FTLD. However, a question whether FUS[1-359]-tg mouse displays behavioural and brain pro-inflammatory changes characteristic for the FTLD syndrome was not addressed. Here, we studied emotional, social and cognitive behaviours, brain markers of inflammation and plasticity of pre-symptomatic FUS[1-359]-tg male mice, a potential FTLD model. These animals displayed aberrant behaviours and altered brain expression of inflammatory markers and related pathways that are reminiscent to the FTLD-like syndrome. FTLD-related behavioural and molecular Journal of Cellular and Molecular Medicine features were studied in the pre-symptomatic FUS[1-359]-tg mice that received standard or new ALS treatments, which have been reported to counteract the ALS-like syndrome in the mutants. We used anti-ALS drug riluzole (8 mg/kg/d), or anti-inflammatory drug, a selective blocker of cyclooxygenase-2 (celecoxib, 30 mg/kg/d) for 3 weeks, or a single intracerebroventricular (i.c.v.) infusion of human stem cells (Neuro-Cells, 500 000-CD34

Indexed as

Amyotrophic Lateral SclerosisAnimalsAnti-Inflammatory AgentsBehavior, AnimalBrainCyclooxygenase 2Frontotemporal Lobar DegenerationGlycogen Synthase Kinase 3 betaInflammationInterleukin-1betaMaleMiceMutationNeuronsRNA-Binding Protein FUSSocial BehaviorAnti-Inflammatory AgentsCyclooxygenase 2FUS protein, mouseGlycogen Synthase Kinase 3 betaInterleukin-1betaRNA-Binding Protein FUSamyotrophic lateral sclerosisanimal modelcelecoxibemotionality and cognitionfrontotemporal lobar degenerationFUS[1-359]-tg miceneuroinflammationriluzolestem cell therapy

Identifiers

PMID32667139
PMCPMC7520339
OpenAlexW3043461726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.